Gavi was a co-convener of COVAX, the leading supplier of free COVID-19 vaccines to low-income countries – which continue to receive COVID-19 vaccines and delivery support through Gavi's regular programmes in 2024–2025.

Safe and effective human papillomavirus (HPV) vaccine offers protection against at least 70% of all cervical cancer cases.

Gavi supports the introduction of the Japanese encephalitis (JE) vaccine into routine immunisation programmes, and funds catch-up campaigns.

Gavi-supported measles and measles-rubella vaccines protect against two devastating diseases.

Gavi helps to prevent cholera outbreaks and control endemic cholera through its support to the Global Oral Cholera Vaccine (OCV) Stockpile and preventive OCV programme.

Gavi helps countries prevent pneumonia through routine vaccination and a one-time catch-up campaign at launch, as well as catalytic introduction support for middle-income countries. Pneumonia killed 725,557 children aged under 5 in 2021 alone.

Gavi supports countries to introduce and roll out the rotavirus vaccine, including catalytic introduction support for middle-income countries, protecting against severe and deadly diarrhoea that killed more than 108,000 children under five in low- and middle-income countries in 2021.

Gavi provides yellow fever vaccine support for its introduction into routine immunisation programmes, as well as funding for campaigns in high-risk countries and an emergency stockpile in case of outbreaks.